Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market & Industry Briefs

Executive Summary

Brief summaries of recent medtech market and industry developments. This month we cover use of fractional flow reserve PCI to avoid unecessary stenting; new European Society of Cardiology guidelines that should increase the use of implantable loop recorders; treating obesity with neurostimulation devices; Asthmatx's positive recommendation from an FDA panel; and the decrease in the number of 510(k) clearances.

You may also be interested in...



Market & Industry Briefs

Brief summaries of recent medtech market and industry developments. This month we cover the transcatheter heart valve market, clinical results on Eurocor's DIOR drug-eluting balloon, additions to Covidien's endomechanical business, and patent disputes in diagnostics.

Market & Industry Briefs

Brief summaries of recent medtech market and industry developments. This month we cover the transcatheter heart valve market, clinical results on Eurocor's DIOR drug-eluting balloon, additions to Covidien's endomechanical business, and patent disputes in diagnostics.

New Developments in Obesity Intervention

With soaring medical costs weighing heavily on the US economy, it's not surprising that obesity has become a target in the health care reform debate. Obesity is costly because it significantly increases the risk of many chronic diseases. Exercise, dieting and prescription drugs have had a limited effect in stemming the tide of obesity, leaving bariatric surgery and other interventional techniques as the primary treatment options for this potentially multi-billion dollar market. But device manufacturers have a challenge ahead of them--to develop more effective, safer, and less invasive obesity therapies that will not only result in long-term weight loss, but will also cut treatment costs and better manage comorbidities.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035228

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel